PerkinElmer has announced the addition of the DELFIA Xpress sFlt-1 kit to its CE-IVD pre-eclampsia product offerings. This kit will enable short-term prediction of pre-eclampsia and aid in diagnosis in the second and third trimesters of pregnancy together with the previously launched DELFIA Xpress PlGF 1-2-3 assay.
In the second and third trimesters of pregnancy among symptomatic women, the concentrations of DELFIA Xpress sFlt-1 and DELFIA Xpress PlGF 1-2-3 assays can be used to calculate a ratio to predict the onset of pre-eclampsia and for aid in diagnosis. The addition of sFlt-1 completes PerkinElmer’s pre-eclampsia product portfolio, allowing different options for managing pre-eclampsia during all trimesters.
“For risk assessment and diagnosis of pre-eclampsia, accurate results enable healthcare to primarily predict and prevent pre-eclampsia and also to provide improved management for all women,” said Petra Furu, GM, Reproductive Health, PerkinElmer. “With the sFlt-1 assay, we offer the ability to better manage and assess this condition throughout all stages of pregnancy.”
The newly launched DELFIA Xpress sFlt-1 is the latest product dedicated to the prediction of pre-eclampsia that includes PlGF kits on various platforms, as well as the recently launched Pre-eclampsia Detection Kit, the first urinary point-of-care kit utilizing Congo Red technology.
